Studies of Thyroid Function in Health and Disease

健康和疾病中的甲状腺功能研究

• 批准号: 8349923
• 负责人: Monica Skarulis
• 金额: $ 67.65万
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349923
• 关键词: Age; Antibodies; Autoimmunity; Biological; Biological Assay; Blood; Board Certification; Body Composition; Clinical; Development; Diagnosis; Diagnostic; Diagnostic Procedure; Discipline of Nuclear Medicine; Disease; Endocrine; Endocrinology; Energy Metabolism; Enrollment; Ensure; Etiology; Failure; Family history of; Functional disorder; Genetic; Health; Human; Hyperthyroidism; Hyperthyroxinemia; Hypothalamic Hormones; Hypothalamic structure; Hypothyroidism; Institutes; Iodides; Laboratories; Laboratory Study; Magnetic Resonance Imaging; Measurement; Metabolism; Natural History; Patients; Pattern; Pharmacologic Substance; Pharmacy facility; Physical Examination; Pituitary Gland; Pituitary Neoplasms; Preparation; Prolactinoma; Protocols documentation; Public Health; Recording of previous events; Recruitment Activity; Resistance; Scanning; Secondary to; Serum; Services; Signs and Symptoms; Somatotropin; Source; Subacute thyroiditis; Technetium; Testing; Thyroid Function Tests; Thyroid Gland; Thyroid Hormones; Thyroid Nodule; Thyroid Stimulating Hormone Secreting Pituitary Gland Adenoma; Thyroiditis; Thyrotropin-Releasing Hormone; Thyroxine-Binding Globulin; Training; Training Programs; Trophoblastic Neoplasms; United States; United States National Institutes of Health; Urine; X-Ray Computed Tomography; cell growth; glycosylation; healthy volunteer; lead-binding proteins; receptor; research study; safety testing; tumor; uptake

Subjects of any age with known or suspected thyroid abnormalities are actively recruited to this natural history protocol. The disorders studied can be broadly defined as hyper- or hypothyroid states and laboratory abnormalities. Hyperthyroid states include but are not restricted to Graves' disease with or without extrathyroidal manifestations; subacute thyroiditis; silent thyroiditis; single or multiple hyperfunctioning thyroid nodules; iodide-induced hyperthyroidism; surreptitious administration of thyroid hormone; trophoblastic neoplasms; "inappropriate" secretion of TSH arising from TSH- producing pituitary tumors or from a non-neoplastic cause, i.e. pituitary resistance to the action of thyroid hormone. Hypothyroid states include primary thyroid failure due to agenesis, autoimmunity or iatrogenic causes; secondary (or pituitary) hypothyroidism, usually resulting from tumors of the pituitary of non-thyrotropic origin such, as growth hormone (GH)-secreting tumors or prolactinomas; tertiary (or hypothalamic) hypothyroidism, usually resulting from a deficiency in the hypothalamic hormone thyrotropin-releasing hormone (TRH), either of unknown etiology or secondary to a pituitary tumor; bio-inactive TSH, either relating to an endogenous abnormality of hypothalamic hormones or secondary to pituitary tumors (and usually related to abnormal glycosylation patterns of the TSH molecule); generalized resistance to thyroid hormone (RTH), a disease which has been shown to be due to abnormalities in the TH receptor. Additionally, conditions or states that result in abnormal thyroid function tests are studied including non-thyroidal illness; abnormalities of serum TH binding proteins leading to euthyroid hyperthyroxinemia or hypertriiodothyronemia; genetic deficiency of thyroxine-binding globulin (TBG); antibody interference in TSH or other thyroid hormone assays. Since TRH in no longer commercially available in the United States, to ensure a continuous source of TRH available for clinical use and research studies, the Pharmaceutical Development Service located in the Clinical Center Pharmacy Department, has produced pharmaceutical grade TRH for human use. Tests of the safety and activity of this new preparation of TRH was conducted healthy volunteers between the ages of 18 and 65 under an IND and this preparation is now used for clinical diagnostics and experimental studies at the NIH.

具有已知或怀疑的甲状腺异常的任何年龄的受试者都可以积极招募该自然历史方案。 所研究的疾病可以广泛定义为甲状腺功能或甲状腺功能下的疾病和实验室异常。 甲状腺功能亢进的状态包括但不限于具有或没有甲状腺外表现的坟墓疾病；亚急性甲状腺炎；无声甲状腺炎；单个或多个甲状腺结节过度功能；碘化物诱导的甲状腺功能亢进；甲状腺激素的秘密给药；滋养细胞肿瘤； TSH的分泌是由TSH产生的垂体肿瘤或非塑性原因，即垂体抵抗甲状腺激素的作用。 甲状腺功能低下的状态包括因发育不全，自身免疫性或医源性原因引起的原发性甲状腺衰竭；继发性（或垂体）甲状腺功能减退症，通常是由非胸膜垂体的肿瘤产生的，例如生长激素（GH） - 分泌肿瘤或催乳素瘤；第三级（或下丘脑）甲状腺功能减退症，通常是由于下丘脑激素甲状腺蛋白释放激素（TRH）的缺乏，无论是病因尚不清楚还是垂体肿瘤的继发性激素；生物无效的TSH，与下丘脑激素的内源异常有关，或继发于垂体肿瘤（通常与TSH分子的异常糖基化模式有关）； 对甲状腺激素（RTH）的普遍抵抗，这种疾病已被证明是由于TH受体异常引起的。 此外，研究了导致异常甲状腺功能测试的状况或状态，包括非甲状腺疾病。血清Th结合蛋白的异常导致甲状腺功能亢进或高三甲状腺素血症的异常； 甲状腺素结合球蛋白（TBG）的遗传缺乏； TSH或其他甲状腺激素分析中的抗体干扰。 由于在美国不再商业上可用的TRH，因此为了确保可用于临床使用和研究的连续TRH来源，位于临床中心药房部的药物开发服务部门已生产了用于人类使用的药物级TRH。 在IND下，在18至65岁之间对TRH进行新准备的安全性和活动的测试进行了健康志愿者，现在该准备工作用于NIH的临床诊断和实验研究。